LEO Pharma account plan
Dermatology research and development
At a glance
LEO Pharma is a Danish, privately held medical dermatology company with 2025 revenue of DKK 13,499 million and more than 4,000 employees in 30 countries.
LEO Pharma A/S is a Danish medical dermatology company, majority-owned by the LEO Foundation with Nordic Capital as co-owner since 2021. It sells more than 20 dermatology brands plus heparin-based Critical Care products in 70+ markets (31 affiliate and 42 partner markets), treating more than 100 million patients a year. In 2025 it reported revenue of DKK 13,499 million (EUR 1,809 million), +10% at CER, adjusted EBITDA of DKK 2,107 million (16% margin) and net profit of DKK 2,489 million. It had 4,265 FTE at year-end 2025 and 4,426 FTE at 30 September 2026. Revenue split in 2025 was Europe 52%, Rest of World 27% and North America 21%.
Business units
Dermatology – Innovative brands (formerly Strategic brands)
DKK 3,023 million in 2025, about 22% of revenueThree global brands: Adtralza/Adbry for atopic dermatitis (the largest product), Anzupgo for chronic hand eczema (U.S. launch September 2025) and Spevigo for generalized pustular psoriasis (licensed from Boehringer Ingelheim on September 30, 2025). Revenue grew 48% at CER in 2025 and 49% at CER to DKK 2,989 million in 9M 2026.
Dermatology – Established brands
DKK 7,968 million in 2025, about 59% of revenueOver 20 standard-of-care treatments including Fucidin, Enstilar, Protopic and Skinoren, sold directly and through alliance markets. Growth was +2% at CER in 2025 and flat (0% at CER) at DKK 6,057 million in 9M 2026, held back by a European distributor transition.
Critical Care
DKK 2,280 million in 2025, about 17% of revenueHeparin-based anticoagulation treatments for hospitals and specialty care, plus Loqtorzi, a PD-1 antibody licensed for Europe from Junshi Biosciences and launched in Germany in January 2026. Revenue was DKK 1,738 million in 9M 2026 (+2% at CER). Led by EVP Critical Care Jean Monin.
Other (contract manufacturing)
DKK 228 million in 2025, under 2% of revenueContract manufacturing of divested products; DKK 177 million in 9M 2026.
Strategic priorities
- Global rollout of Anzupgo
- Complete the launch and rollout of Anzupgo, then label extensions. It was launched in 12 markets with early access in 10 more by 9M 2026, approved in the EU for adolescents in October 2026 and in China for adults on 13 November 2026.
- Spevigo integration and uptake
- Fully integrate Spevigo and accelerate access, with the U.S., Japan and China as priority markets. Quarterly revenue rose from DKK 128 million in Q1 2026 to DKK 178 million in Q3 2026.
- Build a rare genetic skin disease franchise
- Acquired the Replay HSV gene therapy platform in April 2026 and dersimelagon from Tanabe Pharma in September 2026; the FDA granted Priority Review with a decision expected by end of February 2027, and LEO is preparing a potential U.S. launch in 2027.
- Grow established brands through alliance markets
- Alliance markets served through distribution and commercial partners are named as the key growth drivers for the established brands.
- Partnership-led pipeline
- R&D spending rises in 2026 for delgocitinib in lichen sclerosus (Phase 3 DELTA CARE 1, up to 652 patients) and palmoplantar pustulosis, spesolimab in pyoderma gangrenosum, and tralokinumab in pediatric atopic dermatitis.
- 2026 financial targets
- Reaffirmed outlook: revenue growth 9-11% at CER, adjusted EBITDA margin 14-16%, free cash flow excluding BD&L above DKK 700 million, positive reported net profit.
Latest results
In the first nine months of 2026, revenue rose 9% to DKK 10,961 million, or 11% at CER (organic 7%); Q3 revenue was DKK 3,704 million, +12% at CER. North America was the fastest-growing region at DKK 2,673 million (+38% at CER), Rest of World grew 10% and Europe 1%. Gross margin rose to 65% (+4 points), but OPEX rose 22% to DKK 6,317 million on launches, the U.S. sales force and pipeline spending, so adjusted EBITDA fell to DKK 1,873 million (17% margin vs 21%). Net profit was DKK 679 million. Free cash flow was an outflow of DKK 1,057 million after DKK 2,131 million of BD&L payments, and leverage rose to 5.6x LTM adjusted EBITDA. The 2026 outlook was reaffirmed at 9-11% revenue growth at CER and a 14-16% adjusted EBITDA margin.
Investments and deals
- Dersimelagon acquisition
- Closed on 17 September 2026 for USD 275 million upfront, plus USD 160 million on FDA approval and tiered royalties; an oral MC1R agonist for EPP and XLP.
- Replay gene therapy platform
- Acquired on 30 April 2026 for USD 50 million upfront: a pre-clinical HSV gene therapy platform for genetic skin diseases, lead candidate in dystrophic epidermolysis bullosa.
- Spevigo license
- Global license from Boehringer Ingelheim, closed September 30, 2025, for EUR 90 million upfront; LEO's first entry into rare disease within dermatology.
- Fucidin API facility in Ballerup
- A new, fully automated Fucidin API facility opened in Ballerup on 10 September 2026.
- U.S. commercial expansion
- The U.S. sales force was expanded by more than 50% in 2025 to support the Anzupgo and Spevigo launches.
Challenges and risks
- Margin pressure from launches and deals
- OPEX rose 22% in 9M 2026 and the adjusted EBITDA margin fell to 17% from 21%; Replay and dersimelagon are expected to cost 2 points of 2026 margin, and dersimelagon will also weigh on 2027.
- Higher leverage
- Net interest-bearing debt reached DKK 10,438 million at 30 September 2026, with leverage at 5.6x LTM adjusted EBITDA versus 4.4x at year-end 2025.
- Pricing and market access
- The annual report names market access and pricing, including the U.S. Most-Favored-Nation executive order, tight healthcare budgets, tariffs and price reforms in the U.S. and China as key risks.
- Flat established brands and soft Europe
- Established brands were flat in 9M 2026, hit by a European distributor transition; Europe grew 1% at CER, with the UK, Italy and France declining.
- Supply chain and cyber security
- Supply chain disruption and IT and cyber security are listed among the key operational risks.
What leadership says
“We delivered a strong first nine months of 2026, reflecting the momentum we are building across our business. The global roll-out of Anzupgo® continues to expand and the uptake of Spevigo® is accelerating.”
“While Europe has historically been a pharmaceutical heavyweight, we are now facing stagnation in our research pipeline and increasing competition from the US and the rapidly growing Chinese pharmaceutical industry.”
“If medicine is not used, it is of no use.”
Where a supplier can help
- Launch support for Anzupgo and dersimelagon
- With Anzupgo rolling out market by market and a potential U.S. launch of dersimelagon in 2027, suppliers of commercial launch, market access and medical education services fit the launch priorities.
- Commercial efficiency under margin pressure
- OPEX up 22% and a lower EBITDA margin make tools that raise sales force productivity in the expanded U.S. team relevant to the margin challenge.
- Partner and distributor management
- Alliance markets drive the established brands and a distributor transition hurt Europe, so partner management and distribution services tie to that priority and challenge.
- Supply chain and manufacturing resilience
- Supply chain disruption is a named risk and a new Fucidin API facility just opened, opening room for manufacturing, automation and supply planning suppliers.
- Cyber security and AI tooling
- Cyber security is a named risk and the company is adopting generative AI and its Innoviewer asset-scouting platform, which fits security and data providers.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like LEO Pharma?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- LEO Pharma Annual Report 2025
- LEO Pharma is a Danish, privately held medical dermatology company owned by the LEO Foundation (majority) and Nordic Capital: 2025 revenue DKK 13,499 million (EUR 1,809 million), more than 4,000 employees in 30 countries, 70+ markets, more than 100 million patients a year.
- 2025 revenue grew 8% reported and 10% at CER, the third straight year of double-digit CER growth; Dermatology grew 12% at CER and the strategic brands 48% at CER.
- Revenue mix: Dermatology DKK 10,991 million (Strategic brands DKK 3,023 million, Established brands DKK 7,968 million), Critical Care DKK 2,280 million; Europe 52%, Rest of World 27%, North America 21% of revenue, with North America up 35% at CER.
- Profitability turned around: adjusted EBITDA more than doubled to DKK 2,107 million (16% margin, +9 points), net profit DKK 2,489 million after a loss in 2024, free cash flow DKK 1,875 million, leverage down to 4.4x from 12.4x.
- Portfolio went from one to three global strategic brands: Adtralza/Adbry (atopic dermatitis, largest product), Anzupgo (first FDA-approved chronic hand eczema treatment, U.S. launch September 2025, 12 markets) and Spevigo (rare GPP, licensed from Boehringer Ingelheim on September 30, 2025).
- Partnership-led innovation model: oral STAT6 out-licensed to Gilead (USD 250 million upfront, up to USD 1.7 billion), Loqtorzi in-licensed from Junshi for Critical Care, and "over DKK 5 billion available for value-accretive M&A".
- The U.S. sales force was expanded by more than 50%; R&D investment will rise in 2026 (lichen sclerosus and palmoplantar pustulosis trials for delgocitinib, pyoderma gangrenosum for spesolimab).
- 2026 guidance: revenue growth 8-11% at CER, adjusted EBITDA margin 16-19%, free cash flow excluding M&A above DKK 1 billion.
- Key risks named: pricing and market access (including the U.S. Most-Favored-Nation order), supply chain, cyber security, tariffs and tight healthcare budgets.
- LEO Pharma Nine-month interim report (9M) 2026
- 9M 2026 revenue rose 9% to DKK 10,961 million, +11% at CER (organic 7%); Q3 revenue DKK 3,704 million, +12% at CER.
- Innovative brands (renamed from Strategic brands) grew 49% at CER to DKK 2,989 million: Adtralza/Adbry DKK 2,039 million (+7% CER), Anzupgo DKK 507 million (+535% CER), Spevigo DKK 443 million.
- Established brands DKK 6,057 million (0% CER) and Critical Care DKK 1,738 million (+2% CER, led by Loqtorzi); North America +38% at CER to DKK 2,673 million, Europe +1%, Rest of World +10%.
- Gross margin 65% (+4 points) but OPEX up 22% to DKK 6,317 million, so adjusted EBITDA fell to DKK 1,873 million (17% margin vs 21%); net profit DKK 679 million.
- Dersimelagon acquisition from Tanabe Pharma closed in September (USD 275 million upfront, USD 160 million on FDA approval); FDA Priority Review with a decision expected by end of February 2027 for EPP and XLP.
- Free cash flow was an outflow of DKK 1,057 million after the deal (DKK 1,074 million inflow excluding BD&L); NIBD rose to DKK 10,438 million and leverage to 5.6x.
- Anzupgo approved in the EU for adolescents (October) and in China for adults (November); new Fucidin API facility opened in Ballerup.
- 2026 outlook unchanged: revenue growth 9-11% at CER, adjusted EBITDA margin 14-16%, free cash flow excluding BD&L above DKK 700 million.
- LEO Pharma Six-month interim report (H1) 2026
- H1 2026 revenue rose 7% to DKK 7,257 million, +10% at CER (organic 7%); North America +38% at CER, Rest of World +10%, Europe flat (0%).
- Dermatology grew 12% at CER; the strategic brands (Anzupgo, Spevigo, Adtralza/Adbry) grew 50% at CER to DKK 1,888 million and passed DKK 1 billion in a quarter for the first time in Q2 (DKK 1,028 million).
- Established brands fell 1% at CER because of a distributor transition in one European market; Critical Care grew 3%, helped by the European launch of Loqtorzi.
- Gross margin rose to 66% (+3 points) on lower sourcing costs, but OPEX rose 22% (U.S. sales force, Anzupgo and Spevigo launches, pipeline), so adjusted EBITDA fell to DKK 1,247 million (17% margin vs 21%).
- Net profit DKK 279 million (H1 2025: DKK 1,977 million including the Gilead upfront); free cash flow DKK 62 million; NIBD DKK 9,319 million, leverage 4.9x.
- M&A in rare genetic skin disease: Replay's HSV gene therapy platform (April 2026) and an agreement to acquire dersimelagon from Tanabe Pharma (up to USD 435 million upfront and near-term milestones), filed with the FDA for EPP, potential launch in 2027.
- Outlook changed: revenue growth 9-11% at CER (previously 8-11%), adjusted EBITDA margin 14-16% (previously 15-18%), free cash flow excluding M&A above DKK 700 million (previously above DKK 1 billion).
- Christophe Bourdon: Rebuilding Healthcare with Purpose (Insights Care)
- Bourdon, CEO since 2022 (previously CEO of Orphazyme, Amgen U.S. Oncology, Alexion ultra-orphan launches), says he joined for LEO's "strong heritage and unique profile in medical dermatology".
- His mandate was a transformation of operations and faster revenue growth from dermatology; the magazine presents the resulting growth and profitability as laying "the foundation for a potential IPO".
- Growth relies on R&D plus partnerships with industry and research institutions; he cites the Gilead Sciences partnership as the flagship example.
- He warns that Europe faces "stagnation in our research pipeline and increasing competition from the US and the rapidly growing Chinese pharmaceutical industry".
- Patient focus: "the DNA of the company is to keep being there for the 100 million patients we serve annually."
- Sustainability: net zero by 2050, emissions down more than 50% by 2030, 100% renewable electricity at manufacturing sites since 2024.
- Leadership principles: dream big, create followership, focus; he wants the 4,000 colleagues to feel "inspired, confident, and energized".
- Tell Me Why: skin health matters more than you think (Gulf News podcast)
- Frederik Kier, EVP International Operations, frames skin disease as a public health issue with social, work and psychological impact, not a cosmetic one.
- LEO's edge is more than a century "specifically dedicated to skin diseases"; it reaches close to 100 million patients a year (host's figure) with offices in more than 30 countries and operations in 40 more.
- LEO opened a regional office for emergent markets at Expo City Dubai, chosen for connectivity, and plans to expand in the UAE and use it as a hub for the rest of the Middle East.
- A partnership with the Emirates Dermatology Society targets awareness of chronic hand eczema, which he says affects around 5% of the population and is wrongly seen as acute and self-treatable.
- Innovation for LEO means medicines plus education of professionals, patients and relatives: "if medicine is not used, it is of no use."
- He expects AI to help both drug research and the diagnosis of visible skin diseases.
Questions about LEO Pharma
What does LEO Pharma do?
LEO Pharma is a Danish medical dermatology company selling treatments for skin diseases such as atopic dermatitis, chronic hand eczema and generalized pustular psoriasis, plus Critical Care anticoagulation products, in 70+ markets.
What is LEO Pharma's revenue?
2025 revenue was DKK 13,499 million (EUR 1,809 million), +10% at CER. In the first nine months of 2026 revenue was DKK 10,961 million, +11% at CER.
How many employees does LEO Pharma have?
More than 4,000 employees in 30 countries; 4,426 FTE at 30 September 2026.
Who owns and leads LEO Pharma?
It is majority-owned by the LEO Foundation, with Nordic Capital as co-owner. Christophe Bourdon has been CEO since 2022, and Jesper Brandgaard chairs the Board.
What is LEO Pharma's strategy?
Growth through three innovative brands (Adtralza/Adbry, Anzupgo, Spevigo), a partnership- and acquisition-led pipeline now extending into rare genetic skin disease, and improved profitability.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)